The ACOSOG (Alliance) Z11102 (NCT01556243) phase II single arm prospective trial evaluated how well breast-conserving surgery and radiation therapy worked in treating patients with multiple ipsilateral breast cancer. In this touchONCOLOGY interview, we speak with Prof. Judy Boughey (Mayo Clinic, Rochester, MN, USA) who gives an overview on multiple ipsilateral breast cancer and also discusses the ACOSOG (Alliance) Z11102 trial.
The abstract entitled ‘Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance)’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- Could you tell us a little about multiple ipsilateral breast cancer (MIBC) and its improved detection? (0:14)
- What is known about the optimal surgical management of MIBC? (0:36)
- What were the aims, design and eligibility criteria of the ACOSOG Z11102 study? (1:23)
- What were the primary and secondary outcome measures, and how well were they achieved? (2:30)
- What factors impacted local recurrence? (3:48)
Disclosures: Judy Boughey discloses grant/research support from Eli Lilly
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, EMSO 2023
Significant advancements in breast cancer research emerged from EMSO this year. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) […]
Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023
The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!